Taltz® (ixekizumab) – Expanded indication
March 30, 2020 - Eli Lilly announced the FDA approval of Taltz (ixekizumab), for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Download PDF
